Nucor earnings beat by $0.08, revenue fell short of estimates
Cathie Wood’s ARK ETFs have published their daily trades for Monday, July 14th, 2025, revealing a mix of strategic buy and sell actions across various sectors. Leading the trades was the sale of Roku Inc (NASDAQ:ROKU) stock, with a combined sale of 33,963 shares across the ARKK and ARKW ETFs, amounting to a total dollar value of $3,022,367. This continues a trend for ARK, which has been reducing its position in Roku over the past week.
On the buy side, ARK’s ARKG ETF invested in Caris Life Sciences Inc (PRIVATE:CAI), purchasing 52,527 shares with a total dollar value of $1,392,490. This move marks a new investment direction for the fund, which has not reported significant activity in Caris Life Sciences in the previous week’s trades.
The ARKK ETF also sold 171,557 shares of Archer Aviation Inc (NYSE:ACHR), totaling $1,803,064, which follows a similar sale from the previous Friday, suggesting a consistent sell-off strategy for the aviation company.
Guardant Health Inc (NASDAQ:GH) also saw a sell-off, with ARK’s ARKG ETF divesting 27,569 shares, equating to $1,385,342. This trade comes amidst a series of sales in healthcare-related stocks by ARK.
While the focus was on these major trades, ARK’s ETFs continued to adjust their portfolios with smaller transactions, ensuring a dynamic investment approach as market conditions evolve.
Investors following ARK’s ETFs should note the ongoing trends, particularly the reduction in Roku holdings, which could signal a shift in the fund’s confidence in the streaming device company. Conversely, the purchase of Caris Life Sciences might indicate ARK’s growing interest in the healthcare sector, despite the simultaneous sell-off of other stocks in the same industry.
ARK’s daily trade reports offer valuable insights into the fund’s strategies, allowing investors to gauge the direction in which the influential ETFs are moving.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.